A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

Objective. This meta-analysis was conducted to compare the therapeutic efficacy and clinical safety of the combination therapy of apatinib plus chemotherapy with that of chemotherapy alone in patients with refractory or recurrent ovarian carcinoma (OC). Methods. Relevant randomized controlled trials...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chao Hou, Zhuang-Zhuang Jiang, Bo Pan, Xiao-Chun Zhang, Yan-Qing Liu
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/1b224c60f1464489b45cec2f57b3fffb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b224c60f1464489b45cec2f57b3fffb
record_format	dspace
spelling	oai:doaj.org-article:1b224c60f1464489b45cec2f57b3fffb2021-11-15T01:19:43ZA Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis1741-428810.1155/2021/2292907https://doaj.org/article/1b224c60f1464489b45cec2f57b3fffb2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2292907https://doaj.org/toc/1741-4288Objective. This meta-analysis was conducted to compare the therapeutic efficacy and clinical safety of the combination therapy of apatinib plus chemotherapy with that of chemotherapy alone in patients with refractory or recurrent ovarian carcinoma (OC). Methods. Relevant randomized controlled trials (RCT) or case-control studies (CCS) were identified by searching Chinese and English databases up to October 31, 2020. The risk of methodological bias tool and Newcastle–Ottawa scale (NOS) were used to assess trial quality. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to evaluate the therapeutic effects and adverse drug reactions. Subgroup analyses of study type, study sample size, dosage of apatinib, and chemotherapy regimen between treatment group and control group were performed. Publication bias was assessed by funnel plot symmetry, Begg–Mazumdar test, and Egger test. The robustness of our results was presented by removing the trial one by one. Results. Fifteen eligible studies covering 1,020 patients were included in this review and meta-analysis. Among these studies, 8 were RCTs, and 7 were CCSs. Compared with chemotherapy alone, apatinib plus chemotherapy significantly increased objective response rate (OR = 3.55; 95% CI 2.31 to 5.47), disease control rate (OR = 3.04; 95% CI 2.12 to 4.36), and overall survival (OR = 5.03; 95% CI 3.16 to 6.90). Conclusions. The combination treatment of apatinib plus chemotherapy provides better clinical benefits for OC patients when compared to chemotherapy alone and should be recommended for suitable patients with OC after the failure of standard regimens. However, further investigation into future large-scale prospective randomized research is still needed.Chao HouZhuang-Zhuang JiangBo PanXiao-Chun ZhangYan-Qing LiuHindawi LimitedarticleOther systems of medicineRZ201-999ENEvidence-Based Complementary and Alternative Medicine, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Other systems of medicine RZ201-999
spellingShingle	Other systems of medicine RZ201-999 Chao Hou Zhuang-Zhuang Jiang Bo Pan Xiao-Chun Zhang Yan-Qing Liu A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
description	Objective. This meta-analysis was conducted to compare the therapeutic efficacy and clinical safety of the combination therapy of apatinib plus chemotherapy with that of chemotherapy alone in patients with refractory or recurrent ovarian carcinoma (OC). Methods. Relevant randomized controlled trials (RCT) or case-control studies (CCS) were identified by searching Chinese and English databases up to October 31, 2020. The risk of methodological bias tool and Newcastle–Ottawa scale (NOS) were used to assess trial quality. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to evaluate the therapeutic effects and adverse drug reactions. Subgroup analyses of study type, study sample size, dosage of apatinib, and chemotherapy regimen between treatment group and control group were performed. Publication bias was assessed by funnel plot symmetry, Begg–Mazumdar test, and Egger test. The robustness of our results was presented by removing the trial one by one. Results. Fifteen eligible studies covering 1,020 patients were included in this review and meta-analysis. Among these studies, 8 were RCTs, and 7 were CCSs. Compared with chemotherapy alone, apatinib plus chemotherapy significantly increased objective response rate (OR = 3.55; 95% CI 2.31 to 5.47), disease control rate (OR = 3.04; 95% CI 2.12 to 4.36), and overall survival (OR = 5.03; 95% CI 3.16 to 6.90). Conclusions. The combination treatment of apatinib plus chemotherapy provides better clinical benefits for OC patients when compared to chemotherapy alone and should be recommended for suitable patients with OC after the failure of standard regimens. However, further investigation into future large-scale prospective randomized research is still needed.
format	article
author	Chao Hou Zhuang-Zhuang Jiang Bo Pan Xiao-Chun Zhang Yan-Qing Liu
author_facet	Chao Hou Zhuang-Zhuang Jiang Bo Pan Xiao-Chun Zhang Yan-Qing Liu
author_sort	Chao Hou
title	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
title_short	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
title_full	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
title_fullStr	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
title_full_unstemmed	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
title_sort	comparison of chemotherapy used with and without apatinib for patients with ovarian carcinoma who progressed after standard regimens: a systematic review and meta-analysis
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/1b224c60f1464489b45cec2f57b3fffb
work_keys_str_mv	AT chaohou acomparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT zhuangzhuangjiang acomparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT bopan acomparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT xiaochunzhang acomparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT yanqingliu acomparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT chaohou comparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT zhuangzhuangjiang comparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT bopan comparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT xiaochunzhang comparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis AT yanqingliu comparisonofchemotherapyusedwithandwithoutapatinibforpatientswithovariancarcinomawhoprogressedafterstandardregimensasystematicreviewandmetaanalysis
_version_	1718428909875232768

A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

Ejemplares similares